What happened
Shares of Fate Therapeutics(NASDAQ:FATE), a clinical-stage biotechnology company, are sliding in response to interim data from ongoing clinical trials with two of its new drug candidates. Investors unimpressed with the company’s new approach…

Click here to view the original article.